Neuronetics (STIM) to Release Earnings on Tuesday

Key Points

• Neuronetics is expected to report its Q2 2025 earnings on August 5th, with analysts predicting earnings of ($0.08) per share and revenue of $36.80 million.
• The company's stock recently dropped 0.8%, with a trading price of $4.49, while it has a market cap of $296.50 million.
• Goldman Sachs Group Inc. significantly increased its stake in Neuronetics by 2,993.3% in the first quarter, owning about 0.96% of the company post-investment.

Neuronetics (NASDAQ:STIM - Get Free Report) is expected to post its Q2 2025 quarterly earnings results before the market opens on Tuesday, August 5th. Analysts expect Neuronetics to post earnings of ($0.08) per share and revenue of $36.80 million for the quarter. Neuronetics has set its Q2 2025 guidance at EPS and its FY 2025 guidance at EPS.

Neuronetics (NASDAQ:STIM - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.08). Neuronetics had a negative net margin of 53.67% and a negative return on equity of 174.15%. The firm had revenue of $31.98 million during the quarter, compared to analysts' expectations of $29.07 million. On average, analysts expect Neuronetics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Neuronetics Stock Performance

Shares of Neuronetics stock traded up $0.03 on Friday, hitting $4.42. The stock had a trading volume of 637,790 shares, compared to its average volume of 873,752. Neuronetics has a 52-week low of $0.52 and a 52-week high of $5.92. The company has a current ratio of 2.44, a quick ratio of 2.28 and a debt-to-equity ratio of 1.40. The stock has a market cap of $292.21 million, a price-to-earnings ratio of -3.37 and a beta of 1.78. The company's 50 day moving average price is $3.79 and its 200 day moving average price is $3.92.

Insider Buying and Selling at Neuronetics

In other news, EVP Stephen Furlong sold 193,460 shares of the business's stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $4.27, for a total value of $826,074.20. Following the completion of the sale, the executive vice president directly owned 416,593 shares of the company's stock, valued at approximately $1,778,852.11. The trade was a 31.71% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 8.70% of the company's stock.

Institutional Trading of Neuronetics

An institutional investor recently raised its position in Neuronetics stock. Goldman Sachs Group Inc. raised its stake in shares of Neuronetics, Inc. (NASDAQ:STIM - Free Report) by 2,993.3% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 630,393 shares of the company's stock after acquiring an additional 610,014 shares during the period. Goldman Sachs Group Inc. owned approximately 0.96% of Neuronetics worth $2,320,000 as of its most recent SEC filing. Institutional investors own 53.59% of the company's stock.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.